Chagas disease (CD) is a neglected tropical disease caused by the intracellular protozoan that remains a serious public health issue affecting more than 6 million people worldwide. The available treatment includes 2 nitro derivatives, benznidazole (BZ) and nifurtimox, that lack in efficacy in the later chronic phase and when administered against the several naturally resistant parasite strains and present several side-effects, demanding new therapeutic options. One strategy is based on repurposing by testing drugs already used for other illness that may share similar targets. In this context, our previous data on imatinib (IMB) and derivatives motivated the screening of 8 new IMB analogues. Our findings showed that all except 1 were active against bloodstream trypomastigotes reaching drug concentration capable of inducing a 50% of parasite lysis (EC) values < 12 m after 2 h while BZ was inactive. After 24 h, all derivatives were more potent than BZ, exhibiting EC values 1.5–5.5 times lower. Against intracellular forms, 7 out of 8 derivatives presented high activity, with EC values ≤ BZ. LS2/89 stood out as one of the most promising, reaching EC values of 1.68 and 4.9 m on intracellular and trypomastigote forms, respectively, with the best selectivity index (>60) towards the proliferative forms. Physicochemical parameters as well as the absorption, distribution, metabolism, excretion and toxicity properties were predicted to be acceptable and with good chance of a favourable oral bioavailability. The promising results motivate further studies such as and combinatory assays aiming to contribute for a novel safer and effective therapy for CD.